The one thing we have to do is to keep these supply chains open with vaccine ingredients, vaccine production and vaccine distribution. Anything that impedes this is going to be a major source of problems.
The nature of vaccine production is that it's typically geographically concentrated. We have a lot of concentration here in Europe, but also in places like India. It's imperative that we persuade governments here not to engage in export controls and not to fragment the single market, which could possibly happen under the existing EU treaties if different countries, like Belgium for example, decide to ban exports.
The trade policy side of this is extremely important if we are serious about ensuring distribution. It's very important for the commercial case for producing vaccines, because most countries, other than the biggest, need to be able to export in order to make a business case for building such a plant and making such a risky investment.